Today: 9 June 2026
SSE share price slips in London as UK wealth fund spotlights the power grid; Feb update looms
29 January 2026
1 min read

SSE share price slips in London as UK wealth fund spotlights the power grid; Feb update looms

London, Jan 29, 2026, 09:24 GMT — Regular session

SSE shares slipped 0.2% to 2,408 pence by 0924 GMT, retreating slightly from a recent 52-week peak. The stock fluctuated between 2,388 and 2,413 pence during the session, marking a return of UK utilities to investor focus.

Focus has shifted to policy and financing as Britain’s National Wealth Fund unveiled a five-year strategy prioritizing the power grid. The state-backed fund confirmed it has already issued a financial guarantee for SSEN Transmission’s grid upgrade projects. Chief executive Oliver Holbourn told reporters: “We’re going to go faster and in a more focused way.” Reuters

This is significant for SSE, which is heavily focused on networks spending. Back in November, Martin Pibworth described the latest investment push as a “once-in-a-generation opportunity” to modernize critical infrastructure. Jefferies analyst Ahmed Farman added that the plan “brings clarity on the balance sheet and the company’s growth outlook.” Reuters

The broader market edged higher, with the FTSE 100 gaining roughly 0.5% during the session. SSE lagged slightly behind the index in early trading.

SSE’s shares remain close to their year-high levels, having surged sharply over the last 12 months. Some investors are now questioning what upside remains. According to Hargreaves Lansdown data, the stock has gained around 52% over the past year.

Rate moves remain in the background. UK “gilt” yields — the government bond yields that influence the discount rate for steady, regulated cashflows — stayed near 3.75% on the two-year gilt on Wednesday, according to data. Trading Economics

The downside risk remains. Large network and renewables expansions could face planning setbacks, rising expenses, and changing regulatory returns — while a fresh surge in borrowing costs would put the sector’s funding assumptions under pressure.

SSE will pay its interim dividend on Jan. 30 and release its third-quarter trading update on Feb. 4. The company is set to provide fresh details on delivery, spending, and operational trends.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move
Previous Story

HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus
Next Story

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus

Go toTop